Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products

Nutr Res. 2014 Sep;34(9):807-13. doi: 10.1016/j.nutres.2014.08.010. Epub 2014 Aug 29.

Abstract

Advanced glycation end products (AGEs) not only inhibit DNA synthesis but also play a role in diabetic retinopathy by evoking apoptosis and inflammation in retinal pericytes via interaction with a receptor for AGE (RAGE). Similarly, sulforaphane, which is a naturally occurring isothiocyanate that is found in widely consumed cruciferous vegetables, protects against oxidative stress-induced tissue damage. Therefore, we hypothesized that sulforaphane could inhibit AGE-induced pericytes injury through its antioxidative properties. Advanced glycation end product stimulated superoxide generation as well as RAGE gene and protein expression in bovine-cultured retinal pericytes, and these effects were prevented by the treatment with sulforaphane. Antibodies directed against RAGE also blocked AGE-evoked reactive oxygen species generation in pericytes. Sulforaphane and antibodies directed against RAGE significantly inhibited the AGE-induced decrease in DNA synthesis, apoptotic cell death, and up-regulation of monocyte chemoattractant protein 1 messenger RNA levels in pericytes. For the first time, the present study demonstrates that sulforaphane could inhibit DNA synthesis, apoptotic cell death, and inflammatory reactions in AGE-exposed pericytes, partly by suppressing RAGE expression via its antioxidative properties. Blockade of the AGE-RAGE axis in pericytes by sulforaphane might be a novel therapeutic target for the treatment of diabetic retinopathy.

Keywords: AGE; Diabetic retinopathy; Oxidative stress; Pericytes; RAGE; Sulforaphane.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Brassicaceae / chemistry*
  • Cattle
  • Cells, Cultured
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • DNA / drug effects
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / genetics
  • Diabetic Retinopathy / metabolism*
  • Glycation End Products, Advanced / metabolism*
  • Inflammation / prevention & control
  • Isothiocyanates / pharmacology*
  • Isothiocyanates / therapeutic use
  • Pericytes / drug effects*
  • Pericytes / metabolism
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • RNA, Messenger / metabolism
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / metabolism*
  • Retina / cytology
  • Retina / drug effects*
  • Retina / metabolism
  • Sulfoxides
  • Superoxides / metabolism

Substances

  • Chemokine CCL2
  • Glycation End Products, Advanced
  • Isothiocyanates
  • Plant Extracts
  • RNA, Messenger
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Sulfoxides
  • Superoxides
  • DNA
  • sulforaphane